Biocept (NASDAQ:BIOC) Now Covered by Analysts at started coverage on shares of Biocept (NASDAQ:BIOCGet Rating) in a report released on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, Maxim Group cut Biocept from a “buy” rating to a “hold” rating in a research report on Friday, April 14th.

Biocept Trading Down 0.9 %

NASDAQ:BIOC opened at $2.16 on Tuesday. The company has a market capitalization of $1.27 million, a P/E ratio of -0.03 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.91 and a current ratio of 2.07. The stock’s 50 day moving average price is $7.95 and its 200 day moving average price is $13.90. Biocept has a 52 week low of $1.99 and a 52 week high of $47.70.

Hedge Funds Weigh In On Biocept

A hedge fund recently bought a new stake in Biocept stock. Millennium Management LLC bought a new position in shares of Biocept, Inc. (NASDAQ:BIOCGet Rating) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 103,124 shares of the medical research company’s stock, valued at approximately $97,000. Millennium Management LLC owned about 0.61% of Biocept at the end of the most recent quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Biocept Company Profile

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Featured Articles

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.